Evidence map›Paper›PMID 38164768›Full record

ArticleEmerging microbes & infections2024

Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates.

Courtney Woolsey, Robert W Cross, Abhishek N Prasad, Krystle N Agans, Viktoriya Borisevich, Daniel J Deer, Natalie S Dobias, Alyssa C Fears, Mack B Harrison, Megan L Heinrich and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Courtney WoolseyGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Robert W CrossGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Abhishek N PrasadGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0002-4147-2077
Krystle N AgansGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Viktoriya BorisevichGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Daniel J DeerGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Natalie S DobiasGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Alyssa C FearsGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Mack B HarrisonGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Megan L HeinrichZalgen Labs, LLC, Frederick, MD, USA.
Karla A FentonGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Robert F GarryZalgen Labs, LLC, Frederick, MD, USA.
Luis M BrancoZalgen Labs, LLC, Frederick, MD, USA.
Thomas W GeisbertGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
The University of Texas Medical Branch at Galveston · USZalgen (United States) · USTulane University · US

Funding

Regulatory Compliance Core - Galveston National Laboratory BSL4 OperationsUC7AI094660 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Thomas Gary Ksiazek · 2011 to 2026
$208.8M
Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI DIAMOND, MICHAEL S · 2019 to 2023
$40.0M
Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktailR01AI132223 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2017 to 2021
$5.7M
NIAID NIH HHS R01 AI132223NIAID NIH HHS U19 AI142790NIAID NIH HHS UC7 AI094660
6 · The paper itself

Abstract

Lassa virus (LASV) is a World Health Organization (WHO) priority pathogen that causes high morbidity and mortality. Recently, we showed that a combination of three broadly neutralizing human monoclonal antibodies known as Arevirumab-3 (8.9F, 12.1F, 37.2D) based on the lineage IV Josiah strain protected 100% of cynomolgus macaques against heterologous challenge with lineage II and III strains of LASV when therapy was initiated beginning at day 8 after challenge. LASV strains from Benin and Togo represent a new lineage VII that are more genetically diverse from lineage IV than strains from lineages II and III. Here, we tested the ability of Arevirumab-3 to protect macaques against a LASV lineage VII Togo isolate when treatment was administered beginning 8 days after exposure. Unexpectedly, only 40% of treated animals survived challenge. In a subsequent study we showed that Arevirumab-3 protected 100% of macaques from lethal challenge when treatment was initiated 7 days after LASV Togo exposure. Based on our transcriptomics data, successful Arevirumab-3 treatment correlated with diminished neutrophil signatures and the predicted development of T cell responses. As the

Indexed as

Lassa FeverLassa virusAnimalsAntibodies, MonoclonalHumansMacaca fascicularisVirulenceAntibodies, Monoclonalarenavirushaemorrhagic feverLassa virusmonoclonal antibodiesnonhuman primates

Identifiers

PMID38164768
PMCPMC10810630
OpenAlexW4390507396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.